Track the Oxford Biomedica plc stock price and the full management transaction log of the company, a listed equity based in United Kingdom. Shares are quoted on the UK market, under the oversight of RNS (LSE). Market capitalisation: €636.7m. The latest transaction was reported on 25 May 2026 (sold). Among the most active insiders: Natalie Walter. All data is accessible without an account.
8
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€652,452
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Oxford Biomedica plc Buy (bullish), based on 8 analysts. Average price target: £712.00.
15Σ signal
Buys n/a€652,452 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,758 of 29,062 companies
26.6
score / 100
Value
29
Quality
24
FCF yld-0.7%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn39%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
0100.0% of flowLondon Stock Exchange (XLON)ISINISIN GB00BDFBVT43RNS:5700121
8 of 8 declarations
About Oxford Biomedica plc
Oxford Biomedica plc is a UK-based biopharmaceutical company specializing in the development of gene and cell therapies. It focuses on the manufacturing of viral vectors for innovative treatments.